#SFHS2611913AFrance expands reimbursement for NINTEDANIB ARROW in pediatric lung disease indications
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
France expands social security reimbursement for NINTEDANIB ARROW 100 mg and 150 mg capsules to cover additional pediatric uses. The medicine can now be reimbursed for children and adolescents aged 6 to 17 with progressive, clinically significant fibrosing diffuse interstitial lung disease, and for children aged 6 and over with diffuse interstitial lung disease linked to systemic sclerosis. The change matters for hospitals, prescribers, pharmacies, insurers, and families managing these rare serious lung conditions. It may reduce out-of-pocket costs and improve access where clinicians choose this treatment for eligible pediatric patients.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Extends reimbursement for NINTEDANIB ARROW 100 mg and 150 mg capsules to certain pediatric lung disease indications
- Covers children and adolescents aged 6 to 17 with progressive, clinically significant fibrosing diffuse interstitial lung disease
- Covers children aged 6 and over with diffuse interstitial lung disease associated with systemic sclerosis
Obligations
What this law requires
Social security reimbursement coverage for NINTEDANIB ARROW 100 mg and 150 mg capsules must be extended to children and adolescents aged 6 to 17 years treated for progressive, clinically significant fibrosing diffuse interstitial lung disease.
Social security reimbursement coverage for NINTEDANIB ARROW 100 mg and 150 mg capsules must be extended to adolescents and children aged 6 years and over treated for diffuse interstitial lung disease associated with systemic sclerosis.